KalVista Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US4834971032

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nancy Stuart. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Nancy Stuart has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CNCE / Concert Pharmaceuticals Inc Chief Operating Officer 0
US:KALV / KalVista Pharmaceuticals, Inc. Director 14,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nancy Stuart. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KALV / KalVista Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KALV / KalVista Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALV / KalVista Pharmaceuticals, Inc. Insider Trades
Insider Sales KALV / KalVista Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KALV / KalVista Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KALV / KalVista Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nancy Stuart as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-03-06 2023-03-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
D - Sale to Issuer -73,233 0 -100.00
2023-03-06 2023-03-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
U - Other -167,963 0 -100.00
2023-02-16 2023-02-15 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -6,048 262,596 -2.25 8.33 -50,380 2,187,425
2023-01-31 2023-01-30 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -13,200 268,644 -4.68 8.35 -110,220 2,243,177
2023-01-09 2023-01-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -2,893 281,844 -1.02 7.25 -20,974 2,043,369
2022-02-16 2022-02-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -6,049 284,737 -2.08 3.08 -18,631 876,990
2022-02-01 2022-01-28 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
A - Award 21,400 290,786 7.94
2022-02-01 2022-01-28 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
A - Award 99,000 269,386 58.10
2022-01-07 2022-01-05 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -2,894 170,386 -1.67 3.19 -9,232 543,531
2021-03-19 2021-03-18 4 KALV KalVista Pharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 14,000 14,000
2021-02-17 2021-02-16 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -6,049 173,280 -3.37 7.32 -44,279 1,268,410
2021-01-07 2021-01-05 4 CNCE CONCERT PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 51,850 51,850
2021-01-07 2021-01-05 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
A - Award 21,700 179,329 13.77
2020-06-24 2020-06-22 4 CNCE CONCERT PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise -21,238 0 -100.00
2020-06-24 2020-06-22 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale -10,295 157,629 -6.13 11.34 -116,694 1,786,725
2020-06-24 2020-06-22 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 21,238 167,924 14.48 3.79 80,492 636,432
2020-02-19 2020-02-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 68,215 68,215
2020-02-19 2020-02-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
A - Award 45,363 146,686 44.77
2019-12-06 2019-12-04 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (Right to Buy)
M - Exercise -5,896 0 -100.00
2019-12-06 2019-12-04 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -3,416 101,323 -3.26 7.61 -25,996 771,068
2019-12-06 2019-12-04 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 5,896 104,739 5.97 4.41 26,001 461,899
2019-04-02 2019-03-31 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -8,835 98,843 -8.21 12.07 -106,638 1,193,035
2019-02-07 2019-02-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -28,616 5,896 -82.92
2019-02-07 2019-02-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -9,046 107,678 -7.75 13.95 -126,192 1,502,108
2019-02-07 2019-02-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 28,616 116,724 32.48 4.41 126,197 514,753
2019-01-08 2019-01-04 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
A - Award 75,000 75,000
2018-11-30 2018-11-29 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
G - Gift -1,850 88,108 -2.06
2018-07-11 2018-07-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -26,127 89,958 -22.51 17.94 -468,697 1,613,775
2018-07-11 2018-07-09 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -5,291 116,085 -4.36 17.56 -92,890 2,038,011
2018-04-13 2018-03-31 4/A CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -4,418 121,376 -3.51 22.90 -101,172 2,779,510
2018-04-03 2018-03-31 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -4,418 136,376 -3.14 22.90 -101,172 3,123,010
2018-01-26 2018-01-25 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -48,882 0 -100.00
2018-01-26 2018-01-25 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -11,066 140,794 -7.29 20.23 -223,865 2,848,263
2018-01-26 2018-01-25 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 48,882 151,860 47.47 4.58 223,880 695,519
2018-01-08 2018-01-04 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
A - Award 70,000 70,000
2017-11-15 2017-11-15 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
G - Gift -1,100 102,978 -1.06
2017-11-15 2017-11-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -4,215 48,882 -7.94
2017-11-15 2017-11-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1,039 104,078 -0.99 18.57 -19,294 1,932,728
2017-11-15 2017-11-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 4,215 105,117 4.18 4.58 19,305 481,436
2017-07-10 2017-07-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
A - Award 60,000 100,902 146.69
2017-03-09 2017-03-08 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -2,098 0 -100.00
2017-03-09 2017-03-08 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -147 40,902 -0.36 16.04 -2,358 656,068
2017-03-09 2017-03-08 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 2,098 41,049 5.39 1.13 2,371 46,385
2017-01-06 2017-01-04 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
A - Award 70,000 70,000
2016-12-07 2016-12-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -7,100 2,098 -77.19
2016-12-07 2016-12-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -897 38,951 -2.25 8.94 -8,019 348,222
2016-12-07 2016-12-06 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 7,100 39,848 21.68 1.13 8,023 45,028
2016-12-07 2016-11-29 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
G - Gift -1,000 32,748 -2.96
2016-12-07 2015-06-23 5/A CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
G - Gift -1,000 33,748 -2.88
2016-01-08 2016-01-07 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
A - Award 80,000 80,000
2016-01-08 2015-06-23 5 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
G - Gift -1,000 32,748 -2.96
2015-11-12 2015-11-11 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -9,200 9,198 -50.01
2015-11-12 2015-11-11 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -456 33,748 -1.33 22.78 -10,388 768,779
2015-11-12 2015-11-11 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 9,200 34,204 36.79 1.13 10,396 38,651
2015-11-03 2015-11-02 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise X -23,216 0 -100.00
2015-11-03 2015-11-02 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -23,216 25,004 -48.15 24.29 -564,019 607,457
2015-11-03 2015-11-02 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 23,216 48,220 92.85 0.57 13,233 27,485
2015-09-15 2015-09-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -17,000 18,398 -48.03
2015-09-15 2015-09-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -996 25,004 -3.83 19.27 -19,193 481,827
2015-09-15 2015-09-14 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 17,000 26,000 188.89 1.13 19,210 29,380
2015-03-12 2015-03-11 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise X -46,430 23,216 -66.67
2015-03-12 2015-03-11 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
S - Sale X -46,430 10,000 -82.28 15.00 -696,450 150,000
2015-03-12 2015-03-11 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 46,430 56,430 464.30 0.57 26,465 32,165
2014-06-12 2014-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
A - Award 100,000 100,000
2014-06-02 2014-05-29 4 CNCE CONCERT PHARMACEUTICALS, INC.
Employee Stock Option (right to buy)
M - Exercise -10,000 69,646 -12.56
2014-06-02 2014-05-29 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock
M - Exercise 10,000 10,000 0.57 5,700 5,700
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)